Fathom Therapeutics raises $55M to scale AI drug design
What's the deal? Fathom Therapeutics has closed an oversubscribed $55 million Series A extension led by Sutter Hill Ventures. Kos Biotechnology PartnersDealroom has a profile for this one. Try Dealroom → joined through its inaugural life sciences fund, Kos BioVentures. The New York company builds small-molecule drugs using quantum chemistryDealroom has a profile for this one. Try Dealroom →, physics-based simulation, and AI.
What's the endgame? Fathom, formerly Atommap, is developing its Microcosmos platform to model how proteins move and interact with drug molecules at atomic resolution. The approach targets biological sites long considered hard to address with conventional methods. The money will fund its lab-in-the-loop platform and internal discovery programmes.
Why now? The round grew from an original $47 million announced in April, reaching $55 million by May; Kos disclosed its participation in November. It is not a new raise but the same expanded Series A.
What could go wrong? The platform remains preclinical. Its value ultimately depends on turning computation into verified drug candidates — something funding alone cannot prove.
Founded by chief executive officer Huafeng Xu, chief technology officer Yujie Wu, and chief computational scientist Jesús Izaguirre, Fathom pairs internal programmes with external discovery partnerships. Other backers include Lilly VenturesDealroom has a profile for this one. Try Dealroom →, Chemistry, Alexandria Venture InvestmentsDealroom has a profile for this one. Try Dealroom →, and Empire State Development's NY VenturesDealroom has a profile for this one. Try Dealroom →.
The signal: Biotech funding is recovering in 2026, but money is flowing mainly to companies with clinical-stage assets — roughly two-thirds of large rounds in the first half went to firms with candidates already in human trials. Fathom's raise is sizeable for a preclinical, platform-first company, making it a test of whether computational discovery can draw capital on promise alone.
Read more: itjuzi.com
Image credit: Generated with Gemini
